Satellos changes BASECAMP trial endpoint after FDA feedback

MRI-measured muscle fat fraction will replace muscle-force testing as the main efficacy measure in BASECAMP after Satellos Bioscience Inc. TSEMSCL NASDAQMSLE received FDA feedback, the company said on Friday. The 53-boy Duchenne muscular dystrophy study is expected to report placebo-controlled results in Q1 2027.

Satellos said in its Nov. 6 release that it submitted a protocol amendment to replace dynamometry with change in MRI-measured fat fraction of the vastus lateralis, a thigh muscle. It sees the measure, together with clinical endpoints, as potentially supporting accelerated approval of investigational forazapadin.

Satellos is a small Toronto-based clinical-stage biotechnology company developing medicines intended to restore muscle repair and regeneration in degenerative muscle disorders.

Satellos shares NASDAQMSLE last closed at US$6.35 on Nov. 5 at 4:00 p.m. EST, before the announcement. Friday's release describes FDA feedback and a proposed regulatory strategy, without reporting FDA acceptance of the measure as a surrogate endpoint supporting approval.

MRI Becomes The Main Efficacy Measure

BASECAMP is a randomized, double-blind Phase 2 study in ambulatory boys aged seven to nine. It compares forazapadin with placebo over 12 weeks, followed by 36 weeks during which all participants receive the drug.

The change shifts the principal efficacy assessment from muscle force to muscle composition. Fat fraction quantifies the proportion of fat within muscle tissue; Satellos says increasing fat replacement is associated with Duchenne progression, while a reduction may represent muscle regeneration.

Functional outcomes remain among the secondary and exploratory endpoints, alongside muscle-quality assessments and biomarkers. The announcement provides no placebo-controlled efficacy result, statistical comparison or numerical success threshold for the amended primary endpoint.

Read more: Akebia Therapeutics reports noninferiority in vadadustat dosing trial

Satellos points to its open-label adult TRAILHEAD study as supporting evidence. In its July 8 interim report, all four participants showed a decline in MRI-measured fat fraction, with a mean reduction of 3.7 percentage points.

The Nov. 6 release identifies that measurement as involving the biceps brachii, an upper-arm muscle, rather than BASECAMP's thigh-muscle endpoint. The adult study lacks a placebo group, so its findings do not establish a comparative treatment benefit in children.

Satellos reported no serious treatment-emergent adverse events and no treatment-emergent adverse events leading to withdrawal or discontinuation in the four-adult interim dataset. Those observations do not settle safety in the pediatric trial.

"Our goal is clear: if BASECAMP delivers supportive results, we intend to move rapidly toward a potential accelerated approval pathway for forazapadin," Satellos co-founder and chief executive Frank Gleeson said in the release.

Accelerated Approval Still Requires Evidence

The FDA's accelerated-approval programme permits earlier approval for serious conditions with unmet medical needs using a surrogate thought to predict clinical benefit. The agency says companies must still conduct studies to confirm the anticipated benefit, and unsuccessful confirmation can lead to withdrawal.

The Duchenne peer group includes Sarepta Therapeutics, Inc. NASDAQSRPT, whose Jan. 26 update described three-year functional outcomes for ELEVIDYS against an external control group. That comparison differs from BASECAMP's initial randomized placebo-controlled period and provides no direct comparison between the treatments.

Satellos' Aug. 13 financial update forecast funding through 2027. That was a company projection, rather than a new runway assessment accompanying Friday's endpoint announcement.

Read more: uniQure reports US$768.4M liquidity and runway into 2030

The next scheduled efficacy catalyst is BASECAMP's Q1 2027 topline readout after the 12-week placebo-controlled period. It will test forazapadin against placebo using the amended MRI measure and inform Satellos' planned discussions with the FDA about a potential accelerated-approval pathway.